title: Acute effects of the use of estrogens in association with progestogens on postprandial triglyceridemia and vascular reactivity.
abstract: OBJECTIVE
  To assess whether hormone replacement therapy with estrogens in association with progestogens in postmenopausal hypertensive women alters postprandial triglyceridemia and vascular reactivity.
  
  
  METHODS
  A double-blind, placebo-controlled, crossover study was carried out with 15 postmenopausal women (age range: 50 to 70 years, mean = 61.6 +/- 6 years) randomly assigned to 2 weeks of placebo or oral ingestion of 0.625 mg of equine conjugated estrogens and 2.5 mg of medroxyprogesterone, fed a high-fat diet (897 calories; 50.1% fat). Vascular reactivity (VR - % of vessel diameter variation in the fasting period and 2 hours after meals) was measured by using the automated ultrasound method. Lipid profile and glycemia during the fasting period and 2 hours after a high-fat meal were measured.
  
  
  RESULTS
  With placebo, vascular reactivity (VR) decreased from 3.20 +/- 17% during the fasting period to -2.1 +/- 30% 2 hours after the meal (P = 0.041). With the hormone replacement therapy, vascular reactivity decreased from 6.14 +/- 27% during the fasting period to - 0.05 +/- 18% 2 hours after the meal (P = NS). Postprandial triglyceridemia increased as follows: 35 +/- 25% with placebo; and 12 +/- 10% with hormone replacement therapy (P < 0.05).
  
  
  CONCLUSIONS
  In postmenopausal hypertensive women, 2 weeks of hormone replacement with an association of estrogens and progestogens decreased hypertriglyceridemia after a high-fat meal, an effect that may reduce the endothelial dysfunction occurring in the postprandial period.
authors.affiliation: Instituto do Coração, Hospital das Clínicas, FMUSP, São Paulo, SP, Brazil. silviocmsantos@uol.com.br
authors.forename: Silvio C M
authors.initials: SC
authors.lastname: Santos
authors.forename: Jaime Augusto
authors.initials: JA
authors.lastname: Canashiro
authors.forename: Otavio C E
authors.initials: OC
authors.lastname: Gebara
authors.forename: José Mendes
authors.initials: JM
authors.lastname: Aldrighi
authors.forename: Nubia
authors.initials: N
authors.lastname: Vieira
authors.forename: Amit
authors.initials: A
authors.lastname: Nussbacher
authors.forename: Humberto
authors.initials: H
authors.lastname: Pierri
authors.forename: João
authors.initials: J
authors.lastname: Serro-Azul
authors.forename: Maurício
authors.initials: M
authors.lastname: Wajngarten
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Rosano
authors.forename: Jose A F
authors.initials: JA
authors.lastname: Ramires
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood*; D004041:Dietary Fats / Q000008:administration & dosage; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000187:drug effects; D015914:Estrogen Replacement Therapy / Q000379:methods; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood; D008525:Medroxyprogesterone / Q000008:administration & dosage; D008875:Middle Aged; D019518:Postprandial Period; D012307:Risk Factors; D013997:Time Factors; D014280:Triglycerides / Q000097:blood*; D014655:Vascular Resistance / Q000187:drug effects*
chemical_list: D001786:Blood Glucose; D004041:Dietary Fats; D004966:Estrogens, Conjugated (USP); D014280:Triglycerides; D002784:Cholesterol; D008525:Medroxyprogesterone